Ivy Leaf

Metadata

Approved Indications

German Commission E

• Catarrh of the airways
• Symptomatic treatment of chronic inflammatory bronchial diseases

ESCOP

• Productive cough
• Symptomatic treatment of chronic inflammatory bronchial conditions

EMA/HMPC

• Well-established use: Expectorant for productive (chesty) cough
• Traditional use: Relief of symptoms of common cold
• Approved for adults, adolescents, and children from age 2 years

Agreement/Disagreement Between Bodies

All three bodies are in substantial agreement. The indications converge on productive cough and bronchial inflammation. The EMA monograph is the most specific about age restrictions (not for children under 2 without medical advice).

Conditions Treated

• Acute bronchitis (primary indication)
• Chronic bronchitis (supportive)
• Productive cough associated with upper respiratory tract infections
• Respiratory catarrh

Mechanism of Action

Ivy leaf has one of the best-characterized mechanisms of any phytotherapeutic:

1. Indirect beta-2 adrenergic stimulation: The prodrug saponin hederacoside C is metabolized to the active compound alpha-hederin. Alpha-hederin prevents internalization of beta-2 adrenergic receptors on bronchial epithelial and smooth muscle cells, thereby increasing the number of receptors available on the cell surface. This leads to:

   • Increased intracellular cAMP (approximately 13.5% increase under stimulating conditions)
   • Bronchospasmolysis (relaxation of bronchial smooth muscle)
   • Increased surfactant production by alveolar type II cells

2. Secretolytic/mucolytic effects: Stimulation of bronchial glands to secrete more watery fluid, thinning mucus

3. Expectorant action: Facilitated clearance of respiratory secretions

4. Anti-edematous effects: Alpha-hederin reduces mucosal swelling

Key molecular detail: Alpha-hederin specifically affects beta-2 adrenergic receptor binding behavior and dynamics, whereas the structurally related saponins hederacoside C and hederagenin do not directly influence receptor binding. This specificity has been demonstrated in HEK293 cells and human airway smooth muscle (HASM) cells.

[Source: Sieben et al., Biochemistry 2009; Hegener et al., Biochemistry 2004]

Clinical Evidence Summary

Systematic Reviews

• A systematic review of clinical trials identified more than 20 studies, mostly in children with upper airway infections
• Study designs include: randomized placebo-controlled, reference-controlled (vs. acetylcysteine, ambroxol), and open observational studies
• Total patients across clinical and observational studies: >65,000

Key Randomized Controlled Trials

Kruttschnitt et al. (2020) — RCT vs. Acetylcysteine

• Design: Randomized, double-blind, non-inferiority trial
• Population: Adults and children with acute bronchitis
• Comparator: Acetylcysteine (NAC)
• Result: Ivy leaf cough syrup was non-inferior to acetylcysteine
• Significance: Demonstrates ivy leaf is as effective as a standard mucolytic
• [Source: Evidence-Based Complementary and Alternative Medicine, 2020]

Observational Studies (Prospan)

• Multiple post-marketing surveillance studies totaling tens of thousands of patients
• Consistent demonstration of significant improvement in:
  • Coughing fits
  • Sputum production
  • Rales/rhonchi on auscultation
  • Dyspnea
  • Overall disease severity
• Improvements typically seen within 7 days of treatment

Pediatric Evidence

• Majority of studies conducted in children, which is unusual for phytotherapy
• Children ages 2-12 years are the primary study population
• Good tolerability consistently demonstrated

Effect Sizes

• Significant and clinically relevant improvement in Bronchitis Severity Score (BSS) within 7 days
• Non-inferiority to acetylcysteine established [NEEDS-RESEARCH: Exact BSS effect size data from Prospan-specific placebo-controlled trials]

European vs. US/Anglophone Consensus

Prospan is available in over 100 countries and is the world’s #1 selling ivy leaf product. Despite this global presence, it remains outside mainstream Anglophone medical practice.

Safety Profile

Contraindications

• Hypersensitivity to ivy leaf or other Araliaceae family members
• Not recommended for children under 2 years without medical advice

Drug Interactions

• No clinically significant drug interactions reported
• [NEEDS-RESEARCH: Formal drug interaction studies are limited]

Side Effects

• Gastrointestinal: Nausea, vomiting, diarrhea (uncommon, frequency not precisely known)
• Allergic reactions: Urticaria (hives), skin rash, difficulty breathing (rare)
• Overall tolerability is rated as very good across studies

Pregnancy and Lactation

• Pregnancy: Not recommended by EMA due to lack of adequate safety data. However, a retrospective cohort study (n=245 pregnant women) found no increased risk of adverse fetal outcomes with short-term use of ivy leaf extract syrup during pregnancy. [Source: PMC 8602585, 2021]
• Lactation: Not recommended due to insufficient data

Clinical Dosage

Prospan (EA 575) Extract — Syrup

• Duration: Typically 7 days; consult physician if symptoms persist
• Each 5 mL syrup contains approximately 35 mg dry ivy leaf extract

Prospan Film-Coated Tablets

• Adults: Dosing per product-specific recommendations

General Herb Preparation (non-standardized)

• Dried leaf: 0.3 g in herbal tea preparations (per Commission E)
• Note: Standardized extracts are strongly preferred due to variable saponin content in crude preparations

Sources

• EMA Assessment Report on Hedera helix L., folium (Revision 2)
• EMA Community Herbal Monograph on Hedera helix L., folium
• Kruttschnitt et al. (2020). Evidence-Based Complementary and Alternative Medicine.
• Sieben et al. (2009). Biochemistry, 48(15):3477-3482.
• Holzinger & Chenot (2011). Rapid review, PMC 7424313.
• Altmeyers Encyclopedia: Hederae folium entry.
• Prospan Australia product information.

Connections

• Related to Primrose Cowslip (both used in combination cough products)
• Related to Thyme (Bronchipret Thyme-Ivy combination)
• Compare evidence strength with Pelargonium Sidoides